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ABSTRACT 
Head and neck cancer is reported to be the fifth most common cancer globally and 
around 1,200 new patients are diagnosed in Sweden every year. Historically, survival 
rates have been rather constant but have started to improve over the last few decades as 
a result of new and more aggressive oncological treatments. For this reason, there is a 
need to re-evaluate surgical treatment—both its necessity and its morbidity in 
comparison to the oncological treatments available. There is also a risk of higher 
incidence of side effects from newer oncological regimens, which still needs to be 
evaluated. 
 
In this thesis, different populations of head and neck cancer patients from our 
institution have been analysed concerning aspects of treatment, sequelae, and 
rehabilitation. The material is highly applicable to everyday clinical situations.  
 
In paper I, patients diagnosed between1998 and 2002 with metastases in the neck that 
were treated with full-dose external beam radiotherapy (EBRT) were evaluated 
concerning histopathology and clinical outcome, with a view to evaluating the necessity 
of a planned neck dissection after EBRT. One hundred and fifty-six patients were 
included. Overall survival was 62% and disease-specific survival was 76%. There was 
a clinically complete response to radiotherapy in the neck in 63 patients (40%). Of 
these, 15 had viable tumor cells in the neck specimen. In patients who did not achieve a 
clinically complete response, 40% (37/93) had viable tumor cells in the neck specimen. 
Disease-specific survival in patients with viable tumor cells in the neck after EBRT was 
48% (25/52), and it was 90% (93/104) in patients without viable tumor cells.  
 
Paper II describes a retrospective case-control study of patients diagnosed and treated 
for stricture of the upper oesophagus after EBRT for head and neck cancer between 
1992 and 2005. The aim of the study was to identify possible risk factors for stricture 
formation. Clinical parameters were collected from the medical files. The EBRT dose 
delivered to the upper oesophagus was calculated using the dose-planning system data. 
Seventy patients with stricture and 66 patients without were identified. The incidence 
of upper esophageal stricture at the institution during the study period was 3.3%. A 
multivariate analysis showed an increased risk of stricture in patients who received 
enteral feeding during EBRT or with a mean dose of > 45 Gy delivered to the upper 
oesophagus. Treatment of the stricture with Savary-Gilliard bougienage or through-the-
scope balloon dilatation was found to be safe and successful, but often had to be 
repeated. 
 
In paper III, the morbidity of supraomohyoidal neck dissection (SOND) or modified 
radical neck dissection (MRND) combined with EBRT was evaluated regarding 
cervical range of movement, lymphoedema, mouth opening, swallowing, and shoulder 
disability. The patient material was collected from the study population in paper IV. 
Ninety-eight patients who received only EBRT were identified, 25 patients were treated 
with both SOND and EBRT, and 83 were treated with MRND and EBRT. The overall 
incidence of shoulder disability after both types of neck dissection was 18%. SOND 
had no other significant negative effects on the parameters under evaluation at any time 
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point, while with MRND there was significantly reduced CROM and mouth opening 
two months after treatment. After 12 months, only cervical rotation was still 
significantly reduced.  
 
In paper IV, the aim of the study was to evaluate the effect of an early preventive 
rehabilitation programme on functional losses and quality of life. The programme 
started at diagnosis before the start of treatment and was based on self-care after 
receiving instructions from a speech language pathologist and a physiotherapist. The 
patients were instructed to use the training programme during and after the treatment 
period. One hundred and ninety patients were included in the early experimental 
rehabilitation programme. A control group of 184 patients who did not receive early 
rehabilitation was constructed. It was shown that the programme could be implemented 
without delaying the start of oncological treatment, but no positive effects concerning 
survival, weight loss, functional loss, working ability, or quality of life were observed.   
 
The need for a neck dissection after EBRT cannot be determined by clinical 
examination as a high percentage of patients with clinical complete response showed 
viable tumor cells in the neck specimen. When performing a neck dissection, a SOND 
should be considered in suitable patients as morbidity of SOND is low except for 
shoulder disability. An EBRT dose delivered to the upper 5 cm of the oesophagus 
should be kept below 45 Gy to lower the risk of oesophageal stricture, and patients 
should be instructed to continue to swallow even if they receive enteral nutrition during 
treatment. Finally, even though no positive effects of early rehabilitation could be 
shown, the results do not contradict the idea that rehabilitation based on self-care can be 
effective. Efforts should be made to identify rehabilitation that can reduce functional 
losses and improve quality of life. Future rehabilitation programmes should also 
concentrate on identification of proper instruments for selection of patients and for 
evaluation of intervention in head and neck cancer patients.  
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Introduction 
1 INTRODUCTION 
 
1.1 HEAD AND NECK CANCER 
Head and neck cancer is a heterogeneous group of tumours with different clinical 
patterns 1. They are mostly grouped according to their anatomical site, i.e. the oral 
cavity, the rhinopharynx, the oropharynx, the hypopharynx, the larynx, the nasal cavity, 
the sinuses, and the salivary glands. All of these sites can be subdivided further. As in 
most other groups of malignant tumours, they are classified according to the TNM 
system (www.uicc.org). Worldwide, it is considered to be the fifth most common 
cancer with the seventh highest cancer mortality 2. This estimation is highly 
approximate, as cancer registration is not well organised in many parts of the world, 
which might partly explain the large differences in the incidence of head and neck 
cancer between different regions 3. Even though there are deficiencies in documentation 
from the developing countries, there are indications of an increased incidence of head 
and neck cancer in these parts of the world, most likely due to a change in exposure to 
alcohol and tobacco 4. Other reasons for regional differences mainly involve lifestyle 
considerations, including exposure to different head and neck cancer-inducing agents 
such as bethel chewing, hot tea, smoking, alcohol consumption, and human papilloma 
viruses 5-7.  
 
In 2008, there were 1,206 new cases of head and neck cancer in Sweden: 776 males 
and 430 females. This accounted for 2.4% of all new cancers in Sweden that year 8. 
Median age at diagnosis was 66 years, 65 for men and 68 for women 9. As shown in 
Figure 1, cancer in the oral cavity was most frequent, followed by oropharyngeal and 
laryngeal tumours. These proportions were similar for the Stockholm region alone. 
 
Figure 1. Number of patients diagnosed 2008 in Stockholm and Sweden.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: the Swedish Head and Neck Cancer Quality Register (SHNC-QR) 
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Around 45% of the patients in Sweden were at stages III–IV, with similar figures for 
the Stockholm region, as shown in Figure 2. Around 40% of the patients had cervical 
metastasis at diagnosis and more than 20% of the patients were at stage N2 9. 
 
Figure 2. Distribution of stage in patients diagnosed 2008 in Stockholm and Sweden.
      
            
 
                     Stockholm region 
2008 
T-stage % N-stage % 
T1 31.4 N0 57.1 
T2 27.2 N1 9.6 
T3 16.9 N2 23.8 
T4 19.9 N3 3.1 
TX 2.3 NX 4.6 
Missing 2.3 Missing 1.9 
 
 
 
Source: the Swedish Head and Neck Cancer Quality Register (SHNC-QR) 
 
 
1.1.1 Aspects of treatment 
Treatment for head and neck cancer depends on the specific sub-site of the primary 
tumour and on tumour stage. It is also necessary to take into consideration the 
performance status of each patient, as treatment is often very intense with multiple side 
effects. Patients with co-morbidity have poorer survival, irrespective of the choice of 
treatment 10,11. A patient might be regarded as not being operable due to co-morbidities 
with low performance status or if the tumour is unresectable. During most of the 
twentieth century, only surgery and external radiotherapy were considered effective 
against head and neck cancer but at the end of  the century, chemotherapy in 
combination with radiotherapy became more common 12. In the twenty-first century, 
new treatments such as monoclonal antibodies have been incorporated into the 
treatment arsenal 13.  
 
1.1.1.1 Clinical work-up  
At our institution, head and neck cancer patients are examined with a CT-scan or an 
MRI from the base of the skull over the neck and including the thorax, to determine the 
extent of the tumour and to look for distant metastases. Patients are also examined 
under full anaesthesia to allow a thorough clinical examination with biopsies and to 
exclude a second primary in the upper aerodigestive tract. In most cases, an ultrasound-
guided fine needle aspiration is performed to look for regional metastasis. All patients 
are then discussed at a multidisciplinary meeting. The patients are staged according to 
the TNM staging system and a treatment plan is established 14. At our institution, those 
participating at the meeting are the head-neck surgeons, the oncologists, a 
reconstructive plastic surgeon, a pathologist, a maxillofacial surgeon, a dentist, and a 
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coordinator oncology nurse. This multidisciplinary approach provides a forum for 
discussion and allows the coordinator nurse to quickly establish a treatment programme 
and a time schedule for the patient.      
 
The TNM staging system: 
• T (1–4): size or direct extent of the primary tumour; Tis: carcinoma in 
situ; T0: no evidence of primary tumour. 
• N (0–3): degree of spread to regional lymph nodes.  
• N0: tumour cells absent from regional lymph nodes. 
• N1: metastasis in a single ipsilateral (same-side) lymph node, 3 cm or 
less in size. 
• N2a: metastasis in a single ipsilateral (same side) lymph node, more 
than 3 cm but not more than 6 cm in greatest dimension. 
• N2b: metastasis in multiple ipsilateral (same-side) lymph nodes, none 
more than 6 cm in greatest dimension. 
• N2c: metastasis in bilateral (both) or contralateral (opposite-side) lymph 
nodes, none more than 6 cm in greatest dimension. 
• N3: metastasis in a lymph node more than 6 cm in greatest dimension. 
• M (0/1): presence of metastasis.  
• M0: no distant metastasis. 
• M1: metastasis to distant organs (beyond regional lymph nodes). 
Use of an "X" instead of a number or other suffix means that the parameter was not 
assessed. 
 
 NO N1 N2a N2b N2c N3 
T1 Stage 1 Stage 3 Stage 4a Stage 4a Stage 4a Stage 4b 
T2 Stage 2 Stage 3 Stage 4a Stage 4a Stage 4a Stage 4b 
T3 Stage 3 Stage 3 Stage 4a Stage 4a Stage 4a Stage 4b 
T4 Stage 4a Stage 4a Stage 4a Stage 4a Stage 4a Stage 4b 
 
1.1.1.2 Surgery – neck dissection 
1.1.1.2.1 Primary surgery  
Surgery was the only treatment available for these patients until radiotherapy was 
introduced, and radiotherapy was initially intended to replace surgery as treatment 15. 
This has not been the case, however; instead, the two modalities are used together 16. 
Over time, surgeons have strived to produce as little morbidity and disfigurement as 
possible, resulting in a continuous evolution of new techniques 17. Surgery on the 
primary tumour has changed, and today surgery is rarely performed primarily on 
pharyngeal tumours as these mostly respond well to oncological treatments. However, 
in cases where there is no response or where there is recurrence, these patients are 
treated with salvage surgery 18 if possible, often requiring reconstructions with free 
flaps 19. Tumours in the oral cavity are still often subjects for primary surgery, and in 
many cases they require free-flap reconstructions with soft tissue and, in the case of 
mandibular resections, bone also 20. Lower-stage tumours of the oral cavity are often 
treated with surgery alone while those of higher stages are treated with combined 
modalities 21. Concerning laryngeal tumours, small T1a tumours are often treated with 
Alexander Ahlberg 
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surgery while T1b and T2-3 are treated with EBRT alone and T4 are treated with a 
laryngectomy followed by EBRT 22-24, however local traditions are strong and 
guidelines for treatment vary both nationally and internationally. The Department of 
Veterans Affairs Laryngeal Cancer Study Group 25 is a landmark in the development 
towards organ preservation in this field. There are, however, new forms of surgery with 
better organ-preserving capability that might broaden the field for surgery at the 
primary site 26.     
 
1.1.1.2.2 Neck dissection 
Neck dissection was introduced as palliative surgery for head and neck cancer patients, 
but at the beginning of the twentieth century G.W. Crile 27 established the procedure as 
a treatment for head and neck cancer, reducing the risk of regional recurrence 28. The 
more modern form of neck dissection was later established by H. Martin 29. From the 
1960s, neck dissection was part of surgical treatment 30 in combination with 
radiotherapy for patients with regional metastasis (N-positive). Over time, organ 
preservation became more of an issue with a definitive change towards 
chemoradiotherapy without neck dissection in N-positive patients in the 1980s. The 
debate about how to handle these patients and the possible pros and cons of a planned 
neck dissection—regardless of the therapeutic response after radiotherapy—continued 
all through the 1990s 31,32. This issue is further investigated in Paper I in this thesis. 
During the last decade, however, most authors have concluded that there is no need to 
perform a planned neck dissection in N-positive patients who achieve a complete 
response after radiotherapy or chemoradiotherapy 33,34, and if a neck dissection is 
performed, a modified procedure is recommended 35. Parallel to this, a new role for 
neck dissection has evolved as a diagnostic tool in discovering micrometastasis in the 
N0 neck, thereby serving as a prophylactic treatment against regional recurrence. This 
is commonly called a staging, selective, or elective neck dissection and is mostly used 
for tumours of the oral cavity 36,37 due to the risk of micrometastasis 38. There are some 
controversies concerning the classification of different neck dissections 39 but in 
Sweden we commonly use that of the Committee for Head and Neck Surgery and 
Oncology of the American Academy of Otolaryngology-Head and Neck Surgery 
(AAO-HNS), even though other classification systems might be more distinct 40. 
According to the 
AAO-HNS, there are 
three major types of 
neck surgery: 
radical, modified 
radical, and selective 
41. However, this 
classification is 
under contentious 
development 42. 
 
 
 
 
Figure 3. Modified radical neck dissection with preservation of the 
sternocleidomastoid muscle, internal jugular vein and spinal 
accessory nerve, classified according to the AAO-HNS. 
Introduction 
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There is a trend towards less extensive surgery, only removing the regions of the neck 
that are most likely to harbour metastasis. One development, the sentinel node 
technique, can be regarded as an extremely selective neck dissection only removing the 
gateway nodes 43. This technique is certainly promising and might replace the elective 
neck dissection in the future 44. 
 
1.1.1.3 Non-surgical treatment 
The non-surgical treatment mainly consists of radiotherapy, external and internal 
(brachytherapy), chemotherapy given as induction and/or concurrently, and 
pharmacological treatment. 
 
1.1.1.3.1 External radiotherapy 
External-beam radiotherapy (EBRT) is the basis of oncological treatment for head and 
neck cancer, and in this thesis all patients received EBRT 45. EBRT is commonly given 
using photon beams from a linear accelerator. The goal is to deliver a high dose to the 
tumour without damaging the surrounding tissues, especially certain organs that are 
known to be at risk such as the spinal cord, the inner ear, and the salivary glands 46. To 
achieve this goal, dose planning is crucial and is performed using 3-dimensional CT-
based imaging for identification and delineation of the tumour and organs at risk 47,48. 
Treatment is given over a period of up to 7 weeks with one dose of 2.0 Gray (Gy) per 
day, five days a week. Other fractioning for a shorter period with two doses per day, 
e.g. 1.1 + 2.0 or 1.6 + 1.6 Gy, called hyperfractioned radiotherapy, is also used 49,50. 
The reasoning behind this is the possibility of delivering a higher total dose or—in 
accelerated treatment—to deliver the same dose in a shorter time, not giving the tumour 
cells time to recover 49,51. Since treatment goes on for several weeks, there is a risk of 
small changes in patient positioning due to weight loss, changes in the volume of the 
tumour, and changes in the organs at risk. This, and the fact that the patient is not fully 
immobilised during treatment might lead to high radiation doses to surrounding tissues. 
This risk might be reduced by adaptive radiation treatment with new target definition 
during treatment 52. Another feasible way of limiting radiation to normal tissues while 
treating the tumour is the use of proton beam radiation 53,54. There is also increased use 
of intensity-modulated radiotherapy (IMRT), which reduces the irradiation of normal 
tissues 46. 
 
The question of whether there should be pre- or postoperative EBRT has been under 
debate for decades. Some argue against preoperative EBRT since this might be 
negative for surgery, and above all free-flap reconstructions, especially if there is a long 
time delay between the end of EBRT and surgery 55. Other workers have found 
evidence that postoperative EBRT is associated with a higher risk of local recurrence 56. 
Different protocols are used for different primary sites and stages. Even though some 
authors advocated preoperative EBRT for the oral cavity 57, most institutions use 
primary surgery for tumours smaller than T4 with postoperative EBRT depending on 
stage, radicality, and histopathology 21. The relative impact on outcome of pre- and 
postoperative EBRT in oral cancer is presently being investigated in a Swedish national 
study (ARTSCAN II). For pharyngeal cancers, non-surgical treatment tends to cure 
more patients—making surgery superfluous in many cases—so these tumours are 
mainly treated with preoperative EBRT 58 As in the oral cavity, the laryngeal tumours 
Alexander Ahlberg 
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are treated with different modalities depending on stage as described above in section 
1.1.1.2.1.  
 
1.1.1.3.2 Brachytherapy 
Internal radiation, also called brachytherapy, is less frequently used and its use depends 
on local traditions. Brachytherapy means that photon radiation is delivered through 
plastic tube catheters that are implanted around the tumour, making it possible to 
deliver a high dose of radiation directly to the tumour without any beams passing 
through normal tissue. One limitation of brachytherapy is that the tumour has to be 
accessible for implantation of catheters. Some authors argue that smaller tumours can 
be treated with brachytherapy alone while larger tumours—for example, at the base of 
tongue, should be treated with a combination of external and internal radiotherapy 59,60. 
Brachytherapy is used at Karolinska University Hospital, but only about 15% of the 
patients in Paper IV were treated with brachytherapy. 
 
1.1.1.3.3 Chemotherapy and pharmacological treatment 
 As mentioned earlier chemotherapy in combination with radiotherapy has been used 
more frequently after the Veterans Affairs Laryngeal Cancer Study 25. In many parts of 
the world, the combination of EBRT and chemotherapy is very common 61 but in 
Sweden it is still less frequently used; however, there are regional differences 45. In this 
thesis, 23% of the patients in Paper IV and 15% of the patients in paper III received 
chemotherapy in combination with EBRT; none of the patients in the other study 
populations received any chemotherapy. Chemotherapy can be given alone in palliative 
treatment. In curative treatment, it is always given in combination with radiotherapy 
either before radiotherapy (as induction or neoadjuvant), at the same time as 
radiotherapy (as concomitant or concurrent), or after surgery (as adjuvant) 62. The 
combination of radiotherapy and chemotherapy is reported to improve loco-regional 
control and survival rates, at least in patients with advanced disease 63-65. To further 
reduce the risk of distant relapse, there is an increasing use of the combination 
induction and concurrent chemoradiotherapy since induction chemotherapy has been 
reported to reduce distant relapse 66. The limitations of chemotherapy are its side 
effects, in particular the acute side effects, but there is growing evidence of higher rates 
of late toxicity side effects as well 67. There is a lack of research into patient satisfaction 
and quality of life associated with chemoradiotherapy 68.  
 
Since the study by Bonner et al. in 2006, where they found an improved loco-regional 
control for patients with advanced head and neck cancer treated with a concomitant 
combination of high-dose radiotherapy and cetuximab compared to radiotherapy alone, 
there has been growing interest in treatment with monoclonal antibodies 13,69. However, 
no patients included in the studies in this thesis received any molecularly targeted 
agents. Cetuximab, a EGFR-targeting monoclonal antibody, was the first of these drugs 
to be tested in clinical studies and has been shown to significantly improve survival for 
advanced head neck cancers and for patients with recurrent disease 70. These types of 
drugs are rapidly developing into more specific treatments since it is not yet known 
which patients will respond best to these drugs 71.    
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1.1.2 Aspects of complications 
Head and neck cancer patients suffer from a number of side effects—of both the 
treatment and the tumour disease itself. Due to the location of the primary tumours, 
basal functions such as breathing, swallowing, speech, hearing, vision, smell, and taste 
are affected in addition to disfigurement 72-78.  
 
1.1.2.1 Complications induced by neck dissection 
The incidence and severity of complications after a neck dissection are reported to be 
related to type of neck dissection and whether it is combined with radiotherapy or not. 
For example, a selective neck dissection is generally associated with low morbidity 79. 
There are a number of different complications of varying severity that can be divided 
into acute and late complications. 
 
Acute complications are wound infections, chyle leakage, and postoperative morbidity 
such as cardiac problems and thrombosis 80,81. The most common late complications are 
shoulder disability, shoulder pain, reduced cervical mobility, and lymphoedema 82-85. A 
more uncommon but severe late complication associated with neck dissection is carotid 
blow-out bleeding 86. The rate of complications varies between studies, from 3% to 
over 50% 87. These differences are most likely explained by patient selection, type of 
surgery performed and the skills of surgeons. It appears that many postoperative 
complications can be predicted by the preoperative status of the patient 88,89.  
 
To reduce morbidity, neck dissection surgery should be as atraumatic and limited as 
possible without jeopardizing the aim of the surgery, which is to remove the tumour 90. 
Also, pre-, peri-,  and postoperative care must be optimal 79,84,91. Patients with increased 
risk of morbidity, e.g. patients with malnutrion or tracheostomy, could easily be 
identified preoperatively and precautions taken 92. 
 
In Paper III, morbidity after neck dissection has focused on the following parameters: 
cervical range of motion, lymphoedema, swallowing, mouth opening, and shoulder 
disability—which can all be regarded as late complications. None of these parameters 
appear to be related to reduced survival, but most of them are considered to be 
associated with reduced quality of life 93-97. 
 
1.1.2.2 Complications induced by radiotherapy – oesophageal stricture 
Photon beam irradiation induces a number of side effects such as mucositis, dermatitis, 
fibrosis, and xerostomia. There are different terms for these complications; they are 
often called “toxicity” but the term preferred by the National Cancer Institute is 
“adverse event”. Some are acute, such as mucositis and dermatitis, while others are 
late, such as fibrosis of soft tissues and oesophageal stricture. The adverse events are 
graded on different scales according to their severity 98. However, there is no consensus 
as to the grade of toxicity that is often referred to as “acceptable toxicity”. Moreover, 
the level of the adverse event is also poorly reported in many trials 99. 
  
It is not clear why patients react differently regarding the toxicity of radiotherapy. As 
shown by Taylor et al., fractioning and dose is a risk factor for adverse events with 
Alexander Ahlberg 
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hypopharyngeal and laryngeal tumours but not with oropharyngeal tumours. A general 
risk factor for adverse events seems to be the size, the T-stage, of the primary tumour 
100. At the cellular level, the acute mucosal reaction in the oral cavity is caused by 
radiation-induced mitosis of the basal cells in the mucosa. As the turnover of these cells 
is about two weeks, clinical signs of mucositis will develop after this time lag. 
However, there is also a more acute reaction in the mucosa—developing within 
minutes after radiotherapy—that is induced by reactive oxygen species, cytokines, and 
inflammatory mediators released by cells in the mucosa 101. In the skin also, the basal 
cells are destroyed but development of dermatitis is a more long-lasting process due to 
the slower turnover of skin cells. Hair follicles have a faster turnover, which can 
explain the rapid loss of hair, something that can be temporary or chronic, starting soon 
after initiation of treatment. Cytotoxic drugs induce a toxicity to the oral mucosa which 
is similar to that of ionizing radiation, but this is named stomatitis instead of mucositis. 
One major clinical problem is that the combination of these two modalities can 
aggravate the acute mucosal reaction. The acute reaction in skin is characterised by 
vasodilation and increased vascular permeability. This may lead to reduced perfusion, 
with development of fibrosis of small vessels and deposits of foam cells and fibrin 
under the endothelium, similar to arteriosclerosis. The inflammatory state enhances 
fibroblast proliferation, giving rise to an increase in collagen production that causes 
fibrosis of the soft tissues and skin. In the salivary glands, there is also an inflammatory 
response to radiation—causing fibrosis mainly affecting the serous glands—while the 
mucous glands manage better, which is why the saliva is more viscous after 
radiotherapy. In bone, the osteocytes and osteoclasts can be damaged by radiation 
causing osteoradionecrosis, a less frequent but feared and painful complication 102.   
 
Oesophageal pathology such as peptic oesophagitis and candidiasis is common in head 
and neck cancer patients 103. The incidence of oesophageal stricture after radiotherapy 
is below 5% 104,105 whereas it is reported to be around 20% if radiotherapy is combined 
with chemotherapy 106-109. Swallowing problems are very common in head and neck 
cancer patients 110, and can be caused by a number of radiation-induced adverse events 
such as xerostomia, more viscous mucous production, mucositis, oedema of soft 
tissues, and later on by fibrosis and rigidity in these soft tissues and loss of function in 
muscles that are part of the swallowing process 111. 
  
There are several risk factors that are considered to cause oesophageal stricture in head 
and neck cancer patients after treatment. The aim of Paper II was to further investigate 
causes that lie behind this adverse event. One factor that has been suggested to be 
involved is placement of an enteral feeding tube during radiotherapy, either by 
percutaneous endoscopic gastrostomy (PEG) or with a nasogastric tube (NG-tube) 
112,113. Whether the stricture may be caused by this or whether enteral feeding only 
indicates patients at risk is not known 114. It has been speculated that it is gastric reflux 
due to the gastric tubes that causes the stricture, but there is little evidence for this 115-
118. Other possible risk factors that have been reported earlier are hypopharyngeal 
primary tumour, female sex, and hyperfractioned radiotherapy 107. Another risk factor 
discussed is a high dose of radiation delivered to the upper part of the oesophagus 119-
121. The cause of oesophageal stricture in head and neck cancer patients treated with 
radiotherapy is most likely multifactorial.  
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1.1.2.3 Functional impairments 
Losses of function are typically late, chronic side effects that are very difficult to treat, 
and care is directed at alleviation. Xerostomia—dry mouth—is very common in head 
and neck cancer patients; the incidence rate is reported to be 60–90% 122, due to 
reduced saliva production after radiotherapy. Xerostomia in turn causes bad oral health, 
dental problems, changes in taste, speech problems, swallowing problems, and results 
in reduced quality of life 123-125. Oral mucositis further enhances these problems; it 
develops in about 50% of patients 126. These impairments lead to weight loss and a 
prolonged need for enteral feeding, they are costly, and they significantly reduce 
quality of life 127 and need to be studied further 94,128. The functional impairments that 
were examined in Paper IV were related to problems affecting speech, swallowing, 
chewing, motility in the neck and shoulders, mouth opening, and how these problems 
affected weight loss, working ability, and quality of life.   
 
1.1.3 Aspects of rehabilitation 
Rehabilitation may be a feasible way to reduce and alleviate functional impairments in 
head and neck cancer patients, and requires a multi-professional approach 129. Further 
studies on different rehabilitation programmes with evaluation of their outcome are 
much needed and sought after 130. In the past, rehabilitation of patients with head and 
neck cancer has concentrated on a compensatory approach aimed at relieving already 
established functional losses. Many authors now advocate a preventive approach that is 
aimed at preventing these functional impairments from developing 131,132.  
 
It is important to consider all aspects of rehabilitation. Hands-on rehabilitation of well-
defined functional impairments using newly engineered techniques is obviously a very 
straightforward and appealing approach. It is, however, just as important to engage in 
supportive rehabilitation that facilitates the development of a patient’s coping skills and 
confidence. This type of rehabilitation is important, for example, in handling facial 
disfiguration surgery but should be incorporated into all types of rehabilitation 133. The 
reasoning behind this is that rehabilitation is part of our care of the survivors. With 
every success in improving survival comes a new challenge in the form of handling 
survivorship. Most institutions have elaborate guidelines concerning diagnosis and 
treatment of cancer patients, but guidelines for care of the survivors are often lacking. 
The guidelines on survivorship that actually exist are generally designed for the 
specialist sector and not for primary care 134. Focusing on survivorship is at present 
mainly a question for developed countries, but hopefully survival rates will improve in 
the developing countries—which might make survivorship care one of the main global 
tasks in cancer care 135.      
 
1.1.3.1 Rehabilitation of trismus 
The rehabilitation for preventing reduced mouth opening mainly concentrates on 
programmes using different jaw-stretchers or mouth-opening exercises, but there have 
been few studies 136-139. Furthermore, there has been no study comparing the different 
devices available—such as Therabite, the TMJ exerciser 140, and the Acute Medic jaw 
trainer and stretcher. The latter was used in the study presented in Paper IV. Regarding 
the actual treatment of trismus, there are different surgical approaches 141,142.  
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1.1.3.2 Rehabilitation of swallowing 
The process of swallowing is complex, and considering the trauma to the upper 
aerodigestive tract during treatment of head and neck cancer, disturbance of this 
process is understandable. Once in the oral cavity, food is moved onto the teeth by the 
tongue, which also brings the food together after the crushing by the teeth; this forms a 
bolus that can be swallowed. The food is then pushed backward into the pharynx and 
then the airway has to be sheltered, as well as the entrance to the rhinopharynx. The 
bolus of food is then pressed down into the oesophagus by the pharyngeal muscles and 
the base of the tongue at the same time as the upper oesophageal sphincter relaxes. 
Dysphagia in patients with head and neck cancer is associated with aspiration—with an 
increased risk of pneumonia 143,144 and a reduced quality of life 145. 
 
The main reasons for swallowing problems in head and neck cancer patients after 
radiotherapy are thought to be reduced tongue strength, reduced laryngeal elevation, 
reduced tongue base retraction during swallowing, and fibrosis of the muscles involved 
in swallowing 130,131. Thus, most rehabilitation programmes concentrate on maintaining 
tongue strength, tongue mobility, and the mobility of the larynx 132. In the rehabilitation 
programme presented in Paper IV, the exercises consisted of tongue mobility and 
stretching and the Mendelson´s manoeuvre (holding the larynx in its most supine 
position during swallowing, for 2–3 seconds during each swallow).  
 
1.1.3.3 Rehabilitation of speech  
As the voice is produced at the level of the vocal cords and then transformed into 
speech by articulators, such as the tongue and soft palate, these are differently affected 
by head and neck cancer disease and treatment. Obviously the voice is severely reduced 
by a laryngectomy or radiotherapy to the larynx, while speech can be more affected by 
treatment and disease in the oral cavity. Many studies on voice and speech have not 
been conclusive and have lacked the proper instruments for evaluation 146. Most of 
these studies have focused on maintaining the voice in laryngectomy patients 147-149. 
For this reason, a specific rehabilitation programme for head and neck cancer patients 
other than larynx patients is difficult to construct. In Paper IV, the exercises for 
swallowing were also thought to affect speech.   
 
1.1.3.4 Rehabilitation of cervical range of movement  
Neck and shoulder stiffness in head and neck cancer patients 
is probably due to both EBRT and surgery, in particular neck 
dissection. The rationale for rehabilitation of these patients 
with stretching exercises, as in Paper IV, is the same as for 
neck and shoulder stiffness for other reasons 150 and there 
have been studies indicating an effect of these types of 
exercises 95.   
 
 
 
 Figure 3. Measurement of cervical 
range of movement with a Myrin device.  
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1.1.3.5 Rehabilitation of lymphoedema  
Oedema in the head and neck region causes a dull pain and facial disfigurement, and in 
extreme cases lips and eyelids can be so swollen that vision and eating is impaired 151. 
Lymphoedema therapy consists of sequential manual lymphatic drainage of the 
oedematous region according to Vodder’s technique 152,153. This can be combined with 
compression garments 154. The effect of manual therapy for lymphoedema is poorly 
evaluated in head and neck cancer patients and there is a need for prospective studies 
and clear definitions of different levels of oedema 155. In Paper III, lymphoedema was 
evaluated as a dichotomous variable, without grading, by one physiotherapist who is an 
experienced lymphotherapist. 
 
1.1.3.6 Rehabilitation of shoulder disability 
Shoulder disability refers both to impaired mobility in the shoulder joint and to pain in 
the shoulder region after neck dissection. This is a well-known and common morbidity 
that is induced by injury to the accessory nerve, leading to denervation of  the trapezius 
muscle and neuropathic pain with secondary effects in the shoulder such as adhesive 
capsulatis and myofascial pain in muscles around the shoulder 85. This leads to 
problems in daily activities and a reduced quality of life 96. There are different 
rehabilitation approaches to relieve shoulder disability, but there have been few 
prospective randomised studies on these different techniques. The techniques that are 
used are, for example, progressive resistance exercise training 156 and preventive 
exercises to maintain shoulder mobility and strength 157. In this thesis, the impact of 
rehabilitation on shoulder disability was not assessed but such exercises are part of the 
regular physiotherapy at our institution.     
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2 AIMS 
 
The aim of the work described in this thesis was to investigate the outcome of treatment 
for cervical metastasis, to study some severe complications after treatment, and to 
investigate rehabilitation based on self-care for head and neck cancer patients. It was 
my intention throughout the thesis work to perform clinical trials and cohort studies to 
enable direct clinical implementation of the results. 
 
The specific aims of the four papers were: 
 
I. To investigate whether there is a need for a planned neck dissection in the 
N+ patient after full-dose radiotherapy, regardless of the clinical response in 
the neck. 
 
 
II. To identify and evaluate the risk factors for developing an oesophageal 
stricture after radiotherapy for head and neck cancer. 
 
 
III. To determine what possible morbidities two different neck dissection 
procedures might add to those induced by radiotherapy for head and neck 
cancer patients. 
 
 
IV. To implement an early rehabilitation programme and to determine whether 
it could reduce functional impairments and improve quality of life in head 
and neck cancer patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Material and Methods 
3 MATERIAL AND METHODS 
 
3.1 PAPER I – PLANNED NECK DISSECTION 
Study design: a cross-sectional observational study 
 
3.1.1  Patient material 
Five hundred and fifteen consecutive patients treated between 1998 and 2002 in the 
well-defined county of Stockholm, Sweden, with squamous cell carcinoma of the head 
and neck and neck metastasis could be identified. Those who had received EBRT of > 
60 Gy with a complete response at the primary site followed by a planned ND were 
included in the study. The patients’ medical records were reviewed. Patients treated 
with chemotherapy (induction and/or concomitant) were excluded, as were patients 
whose medical record was incomplete regarding information about the clinical outcome 
after EBRT or if the pathology report was missing or incomplete.  
 
3.1.2 Treatment  
Radiotherapy was given either at Karolinska Hospital, Södersjukhuset or Karolinska 
Hospital, Radiumhemmet. The doses were planned according to the local guidelines in 
Stockholm.  
 
ND was performed according to the local guidelines in Stockholm, at a single 
institution (the ENT clinic at Karolinska University Hospital in Solna). Patients were 
operated four to six weeks after termination of EBRT if there was a complete response 
at the primary tumour site according to an endoscopic examination with the possibility 
of taking biopsies. A planned ND was carried out in all patients who had metastasis in 
the neck at the time of diagnosis, irrespective of the clinical response to EBRT. The 
regions included in the ND normally depended on the site of the primary tumour and 
the extent of disease in the neck before EBRT, and were not dependent on the clinical 
response. 
 
3.1.3 Clinical outcome 
Palpatory findings in the neck 4–6 weeks after radiotherapy were used as a parameter 
for evaluation of the clinical response to EBRT. Patients were categorised either as 
having no response/partial response (NR/PR) or a complete response (CR) depending 
on whether a palpatory mass was found or not found in the neck. During the period 
1998–2002, no regular radiology examinations after EBRT were included in the 
follow-up protocol. If the pathology report stated that there were viable malignant cells 
in the neck specimen, the patient was recorded as being histopathologically positive 
(PAD+); if not, the patient was histopathologically negative (PAD-). Data concerning 
recurrence, site of recurrence, death, and cause of death were correlated to the clinical 
response and histopathology report. 
 
Patients with primary tumour in the tonsillar fossa or the base of the tongue were 
analysed separately because of earlier studies showing that tumours arising from 
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Waldeyer´s ring might be more readily controlled by radiotherapy than those 
originating from other sites in the head and neck region. 
 
Follow-up time in this material was between two and seven years with a median 
follow-up time of 4.4 years. 
 
3.1.4 Statistical methods 
The comparisons of differences in proportions were made using the chi-square test for 
independence, and with Fisher’s exact test when necessary. 
 
Survival time was calculated from the date of diagnosis to the date of death, or if the 
patient was still alive, to 31 December 2004. Survival curves were estimated using the 
Kaplan-Meier method.  
 
In the analysis of cause-specific survival, deaths due to causes other than head and neck 
cancer were treated as censored observations at the time of death. Tests for differences 
in survival times were performed using the log-rank test.  
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3.2 PAPER II – OESOPHAGEAL STRICTURE 
Study design: a nested retrospective case-control study 
 
3.2.1 Patient material 
We continuously identified and registered all patients with upper oesophageal stricture 
after external beam radiotherapy (EBRT) at our department during the years 1992 to 
2005. All the patients included were initially diagnosed as having head and neck cancer 
at the Department of Otolaryngology and Head and Neck Surgery, Karolinska 
University Hospital, Solna, Sweden, between 1987 and 2005. The study sample was 
divided into two time periods based on the year of the EBRT, 1987–1999 and 2000–
2005, as there was a change in EBRT treatment between 1999 and 2000. Calculation of 
incidence was based on the time period 1992–2005 due to lack of earlier data. The 
population base during this time period consisted of 1,805 patients.   
 
Patients with swallowing difficulties and clinical signs of an oesophageal obstruction 
were examined with conventional swallow X-ray using barium contrast and endoscopy. 
Diagnosis of stricture of the upper oesophagus was made by an endoscopic procedure 
under general anaesthesia, except in one case in whom only an X-ray examination with 
swallowing of barium contrast was performed. A control group of patients without any 
reported swallowing problems was constructed. This was done by sending a short 
questionnaire to all the patients without documented stricture or dysphagia in the 
medical files from three different time periods, spread out over the same time period as 
that of the inclusion period of patients with stricture.  
 
In order to make a general description of the strictures of the upper oesophagus, these 
were classified into three subgroups according to the findings at endoscopy for 
diagnosis of dysphagia or treatment of stricture. When more than one endoscopy was 
performed, the patient was classified according to the highest grade of stricture found. 
In grade I, the stricture could be passed with a rigid oesophagoscope 7 × 10 mm wide 
and the stricture could be dilated. In grade II, the stricture could not be passed by the 7 
× 10 mm scope but could be dilated, and after dilatation the oesphagoscope could pass 
the stricture. In grade III, there was total obliteration of the oesophagus.   
 
The medical records of all patients were collected and analysed according to a data 
matrix including the following parameters: EBRT dose (the given dose), survival, 
tumour localization and stage, use of NG tube and PEG, weight changes during EBRT, 
oral mucositis, and treatment of the stricture. In order to make a general description of 
the strictures of the upper oesophagus, these were classified into three subgroups, 
grades I–III, according to the findings at endoscopy for diagnosis of swallowing 
disorder or treatment of stricture.  
 
3.2.2 Exclusion criteria 
Patients treated with chemotherapy were excluded, as were patients with incomplete 
medical records. Patients who had had swallowing disorder(s) before diagnosis of the 
present tumour disease were also excluded. Fourteen patients were excluded as a result 
of these criteria. 
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3.2.3 Radiotherapy 
EBRT was given at two different treatment centres in Stockholm, Södersjukhuset and 
Radiumhemmet (parts of Karolinska University Hospital) and dose plans were 
constructed according to local guidelines. After 1998, the target delineation was 
changed according to new guidelines from the Swedish ARTSCAN study group. These 
guidelines were then gradually implemented for all head and neck cancer patients. It 
was decided that the irradiation volumes and the total dose given to unaffected tissue, 
e.g. the contralateral neck, should be 46 Gy. Earlier, the dose given to elective nodes 
was the same as given to macroscopic tumour. As a result of this change, smaller 
volumes were treated with high doses and a larger proportion of normal tissue could be 
spared. In addition, the larynx was blocked from the anterior-posterior fields if it was 
not included in the planning target volume. 
  
Patients had a CT scan done in supine position at 10- or 5-mm intervals covering an 
area from the base of the skull down to the chest. The CT scans were transferred to the 
treatment-planning system (TMS; Nucleotron, Veenendaal, the Netherlands) in which 
the target and critical structure volumes were delineated. Dose-planning treatment data 
were stored for all patients. 
  
Data for a subgroup of patients with stricture and for the control group treated at 
Radiumhemmet were retrieved from the archive in the TMS system. The oesophagus 
was delineated on each CT image for each patient. The differential and cumulative dose 
volume histograms (DVHs) of the upper 5 cm of the oesophagus were assessed for 
each patient. From the cumulative DVHs, it was possible to calculate the mean dose 
delivered to the upper 5 cm of the oesophagus for this subgroup of patients.  
 
3.2.4 Statistical methods 
Test of equality of distribution was done with the chi-square test, or Fishers’s exact test 
when appropriate. Difference of means was tested with Student’s t-test after assessing 
the normality assumption. Odds ratios (ORs) for potential risk factors in developing a 
stricture were estimated using logistic regression. In the logistic regression analysis, the 
categories of stage and site were analysed as separate indicator variables. A 
multivariate analysis was done with the most interesting and important factors from the 
univariate analysis. All analyses were done using SPSS for Windows version 17.0.1 
(SPSS Inc., Chicago, IL). 
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3.3 PAPER III - MORBIDITY OF NECK DISSECTION  
Study design: a prospective cohort study 
 
3.3.1 Patient material 
Patients included in the early-rehabilitation study described in Paper IV served as the 
population base for this study. From this cohort, patients who had met with the 
physiotherapist (PT) were retrieved; most of these patients had also met with the 
speech-language pathologist (SLP). These patients were then divided into three groups 
according to the treatment given: 
  
• external beam radiotherapy (EBRT) + supraomohyoidal neck dissection 
(SOND) 
• EBRT + modified radical neck dissection (MRND)  
• EBRT only 
 
These groups were then compared concerning cervical range of motion (CROM), 
mouth opening, lymphoedema, shoulder disability, and swallowing.  
 
The head and neck range of movement and mouth opening (interincisial distance 
between upper and lower left front teeth) were measured before the start of treatment 
and at all follow-ups. The CROM (flexion-extension, rotation, and lateral flexion) was 
measured with a Myrin device (an inclinometer) 158 that measured grades of movement, 
which is a well-established method 159. Range of motion was measured in full range, 
i.e. rotation all the way from left to right, from full extension to full flexion, and from 
lateral flexion to the left to lateral flexion to the right.  
 
Lymphoedema was evaluated clinically as a dichotomous variable (yes/no) by the PT 
who is an experienced lymph therapist.  
 
Shoulder disability was also evaluated clinically by the PT within 2 months after the 
ND, and was considered established in cases of obvious weakness when the patient was 
asked to lift his/her shoulder to the ear and abduct and flex his/her extended arm, or in 
the case of an obvious shoulder droop. 
  
The following swallowing parameters were clinically evaluated: oral manipulation and 
transport of bolus, presence of aspiration, laryngeal elevation, need for several 
swallows, delayed initiation of swallowing, and nasal regurgitation. Aspirations were 
noted as cough, need to clear the throat, wet voice, or sudden breathing difficulties. 
 
3.3.2 Surgery 
Surgery was done according to local guidelines at the Department of Otolaryngology 
and Head and Neck Surgery at Karolinska University Hospital where all surgical 
procedures were performed. 
  
Neck dissection was done either as MRND or SOND. In MRND as classified in the 
present study, the accessory nerve is mostly spared but the sternocleidomastoid muscle 
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is sacrificed and nodal levels I–V are removed. In SOND as classified in the present 
study, both the accessory nerve and the sternocleidomastoid muscle are spared, with 
removal of nodal levels I–III and in this study level IV also in some cases, which is 
referred to as extended SOND 41. The extended SOND patients were analysed together 
with the SOND patients.   
 
Patients underwent EBRT before or after neck dissection, i.e. preoperatively or 
postoperatively. Patients with the primary tumour in the oral cavity or salivary glands 
were mainly treated with ND before EBRT. They were therefore evaluated by the PT 
or SLP for the first time 4–6 weeks after surgery in connection with the start of EBRT. 
In patients who underwent EBRT before surgery, ND was performed in cases of 
suspected or manifest residual tumour in the neck. These patients were evaluated for 
the first time by the PT and SLP before the start of any treatment. 
 
3.3.3 Statistical methods 
Differences in distribution between the three treatment groups and nominal variables 
were compared using the chi-square test for independence or, when appropriate, 
Fisher’s exact test. Continuous variables were modelled using linear regression. In 
these models, the treatment effect was estimated using two dummy variables. When 
baseline values were available, these were included in the regression models to control 
for potential initial imbalances. Results from these models are presented as mean 
differences together with 95% confidence intervals. P-values from the models refer to 
F-tests.  
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3.4 PAPER IV - EARLY REHABILITATION 
Study design: a prospective cohort study 
 
3.4.1 Patient material 
This study was based on a clinical development programme financed by the Swedish 
Cancer Society and structured as a prospective non-randomised study comparing two 
parallel groups, one group undergoing experimental early preventive rehabilitation and 
the other group not being offered a systematic rehabilitation programme. Patients were 
included consecutively into both groups over 3.5 years and the first year of inclusion, 
2004, functioned as a pilot study. Thus, no selection of patients was done. 
 
Patients diagnosed with head and neck cancer in Stockholm from 1 January 2004 to 31 
July 2007 who were to receive EBRT with curative intent were included in the study. 
The patients receiving EBRT at the southern unit (Södersjukhuset) were included into 
the rehabilitatiton programme and those treated at the northern unit (Radiumhemmet) 
served as a control group. 
  
Patients included in the study group met before the start of treatment with an SLP and a 
PT who were also part of the research team. Patients included were sent a letter about 
the study directly after diagnosis, to make sure they received information about the 
study before the start of treatment.  
 
3.4.2 Speech-language pathologist intervention and evaluation 
All the patients in the study group were examined by the SLP before EBRT and 3 
months after completion of therapy. The patients were instructed, both verbally and 
with written information, on how to perform mobility exercises for the tongue and 
larynx (Mendelson’s manoeuvre) at least once and preferably twice a day at home 
during the course of EBRT, and for 3 months after termination of treatment. At the 
clinical screening of swallowing, the 
patient was asked to complete one 
swallow of two bolus sizes (5 ml and 15 
ml) of four consistencies: thin liquid, 
thick liquid, paste, and cookie. Movement 
of the floor of the mouth, and hyoid and 
thyroid cartilage was evaluated by manual 
palpation during the act of swallowing. 
Voice and articulation were perceptually 
assessed by the SLP and the motility of 
the tongue was assessed with tongue 
exercises.  
 
3.4.3 Physiotherapy intervention and evaluation 
The patients had an appointment with the PT before the start of EBRT and follow-ups 
were performed at 2, 6, and 12 months after termination of treatment. The patients 
received written and verbal instructions about exercises and stretching of muscles of the 
head and neck in order to maintain mobility in the EBRT-exposed areas. The 
Figure 4. Tongue exercises 
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prevention of trismus consisted of exercises with the “Acute Medic jaw trainer and 
stretcher” (www.acutemedic.com, Sweden). 
 
3.4.4 Effect of treatment and rehabilitation 
Since patients in the control group did not meet the SLP or PT for evaluation of 
functional loss, all patients in both cohorts who were planned for curative EBRT at the 
weekly multiprofessional treatment meeting were sent a set of questionnaires before the 
start of treatment and 6 months after termination of treatment, i.e. last surgery or last 
day of EBRT or brachytherapy. The questionnaires used were EORTC-QLQ-C30, 
EORTC-H&N35 (the European Organisation for Research and Treatment of Cancer), 
HADS (Hospital Anxiety and Depression Scale), and a project-specific questionnaire. 
 
3.4.4.1 Key measure for integration of the programme 
The key measure used to evaluate the integration of the intervention was the length of 
time between the date of diagnosis and the start of EBRT.  
 
3.4.4.2 Key measures for improvement and study endpoints 
Weight loss and 2-year survival were chosen as the principal measures of effect. 
Secondary outcome measures were sick leave, self-reported loss of function, HRQOL, 
and anxiety/depression. 
 
3.4.4.3 Treatment  
EBRT was given at two different radiotherapy centres in Stockholm and dose plans 
were constructed according to local guidelines. Chemotherapy was given either as 
induction treatment or as concomitant treatment. Brachytherapy was mainly used for 
patients with tumours at the base of the tongue and for some cases with tumour in the 
mobile part of the tongue or the floor of the mouth.   
 
Surgery was performed according to local guidelines at the Department of 
Otolaryngology and Head and Neck Surgery at Karolinska University Hospital 
following the same guidelines for both groups.   
 
3.4.4.4 Follow-up 
All patients were followed up for at least two years according to set guidelines, with 
visits every third month for the first 2 years and every six months thereafter.  
 
3.4.5 Statistical methods 
Survival time was calculated from the date of the multi-professional treatment meeting 
to the date of death, or until the common date for the end of survival follow-up, 1 
August 2009. Survival was estimated according to the Kaplan-Meier technique and 
differences in survival times were tested using log-rank test. Confidence interval for the 
reported survival differences refers to the fixed 2-year time point. 
 
Continuous variables were analysed using linear regression models. In these models, 
intervention was included in the model as a categorical variable taking the value of 0 
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for the control group and 1 for the study group. For some continuous outcome 
variables, baseline values were available. In these cases, models were estimated 
including the baseline values as well as the intervention variable. Differences in 
categorical variables were tested using Fisher’s exact test. Binary outcomes were 
modelled using ordinary logistic regression models. For ordinal variables, distributional 
comparisons were performed using the Mann-Whitney U-test and the ordinal outcomes 
were modelled using the proportional odds model. The exponentiated intervention 
coefficient in these models can be interpreted as the ratio (between the study group and 
control group) of the odds of being in a higher (worse) rather than lower (better) 
category. All effects from the regression models are presented together with 95% 
confidence intervals.    
 
3.5 ETHICS 
All studies included in this thesis were conducted according to the declaration of 
Helsinki. The study in Paper II on oesophageal stricture was approved by the the 
Research Ethics Board of Stockholm. Concerning the studies in Paper I on planned 
neck dissection and in Papers III and IV on morbidity of neck dissection and 
rehabilitation, the Research Ethics Board of Stockholm judged that no ethical approval 
was required as they were regarded as clinical development programmes. Such 
assessments by ethical boards can be troublesome when papers are submitted to peer-
review journals, as these often demand approval by an ethical board.   
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Results 
4 RESULTS 
 
4.1 PAPER I – PLANNED NECK DISSECTION  
A total of 156 patients were included in the study. 
 
4.1.1 Histopathological outcome 
One third of the patients (52/156) had viable tumour cells in the neck specimen after 
EBRT. There was a CR in 40% (63/156) of the patients, and among these 24% (15/63) 
had viable tumour cells in the neck. In patients with palpable mass in the neck, 40% 
(37/93) were found to have viable tumour cells. There was no significant difference in 
incidence of viable tumour cells between the N1 group with CR (10%, 5/51) and the 
N2–3 group with CR (10%, 10/105). In N1 patients with viable tumour cells in the 
neck, there was no significant difference between those with a CR (5/51) and those 
with residual disease (5/51). However, the incidence of viable tumour cells was 
significantly lower (p = 0.012) in N1 patients (20%, 10/51) than in the N2–3 group 
(40%, 42/105).  
 
Among patients with the primary tumour in the tonsil or base of tongue 26% (22/85) 
had viable tumour cells, 16% (5/31) of those with CR had viable cells. This is 
significantly lower when compared to all other sites (30/71, 42% and 23/71, 32%, 
respectively). (These figures differs from line 2, table VII in Paper I where there is an 
error.)   
 
4.1.2 Clinical outcome 
The incidence of ipsilateral recurrences with or without another recurrence site in 
patients with viable tumour cells in the neck specimen was 15% (8/52), and it was 2% 
(2/104) in patients without viable tumour cells in the neck specimen. The risk of an 
ipsilateral recurrence was almost the same in patients with a CR (6%, 4/63) as in those 
with PR/NR (6%, 6/93).  
 
The incidence of ipsilateral and overall recurrences in patients with viable tumour cells 
in the neck specimen was more than doubled in patients with a CR after EBRT (80%, 
12/15) compared to those who still had a palpatory mass in the neck (41%, 15/37). 
There was a significant difference when these two groups were compared regarding 
cause-specific deaths (p = 0.014). The incidence of cause-specific deaths was 73% 
(11/15) in patients with a CR and viable tumour cells as compared to 43% (16/37) 
when there was a PR/NR and viable tumour cells.  
 
Overall survival was 62% and disease-specific survival was 76% in this material.  
There was no significant difference in disease-specific survival between N1 patients 
(25%, 13/51) and patients with N2–3 (24%, 25/105) (p = 0.91). There was also no 
difference between the groups when comparing only those with a CR (N1: 27%, 7/26; 
and N2–3: 24%, 9/37) (p = 0.95). 
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Patients with tumours arising from the tonsils or base of the tongue had a significantly 
better outcome with a disease specific survival of 88% (70/85) compared to 68% 
(48/71) for patients with tumours at all other sites.   
   
Viable tumour cells in the neck specimen following EBRT indicated a poor prognosis 
with a disease-specific death rate of 52% as compared to 10% in patients with no viable 
tumour cells in the neck (Figure 5).  
 
 
Figure 5. Deaths according to histopathological findings in neck specimens. 
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4.2 PAPER II – OESOPHAGEAL STRICTURE 
Seventy patients with irradiation-induced stricture of the upper oesophagus were 
identified and evaluated between 1992 and 2005. All patients had undergone EBRT for 
head and neck cancer between 1987 and 2005. Sixty-six patients were included in the 
control group. Cases and controls were well-matched for age and gender, but not for 
year of diagnosis. 
 
The total number of patients irradiated with curative intent for head and neck cancer 
during the two periods was calculated. Based on this calculation, the total incidence of 
irradiation-induced oesophageal stricture in patients treated with radiotherapy for head 
and neck cancer during 1992–2005 was 3.3% (59/1,805). A subgroup analysis of 
patients treated between 1992 and 1999, and between 2000 and 2005, showed an 
incidence of irradiation-induced oesophageal stricture of 3.8% (28/740) and 2.9% 
(31/1065), respectively. Thus, the difference in incidence was not statistically 
significant (p = 0.316). 
 
4.2.1 Stage and site as risk factors 
Tumour stage and primary site of the tumour are presented in Table 1. The stricture 
group and reference group were similar with regard to stage. There was no significant 
difference in median survival time between cases (9.2 years, 95% CI: 6.7–11.7) and 
controls (12.3 years, 95% CI: 8.7–160). Univariate analysis of risk parameters for 
developing a stricture showed a numerical but non-significant increase in odds ratio for 
patients with oral tumours and oropharyngeal tumours. The risk of developing a 
stricture was not related to having a primary tumour in the hypopharynx or epipharynx. 
There was a significant reduction in odds ratio for patients with primary tumour in the 
larynx. 
 
Patients with primary tumour in “other sites” (involving a number of different sites) 
appeared to have a lower risk of developing a stricture. We repeated all calculations 
with such patients excluded from both the controls and cases, to make sure that this 
group did not confound the outcome. There was no significant difference in the results, 
however, except for wider confidence intervals.   
 
4.2.2 NG tube and PEG as risk factors 
There was a high incidence of patients receiving tube feeding among the stricture 
patients. In patients using enteral nutrition in the stricture group, 67% (31/46) used only 
an NG tube and 33% (15/46) used the combination of an NG tube followed later by a 
PEG; two of these patients received PEG before the start of EBRT.  
 
There was higher loss of weight in the stricture group than in the reference group 
during EBRT, even though most patients in the stricture group had an NG tube and 
PEG. In the stricture group, only 4.9% (2/41) gained weight during EBRT as compared 
to 26% (9/34) in the reference group. 
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4.2.3 Surgery as a risk factor 
In the stricture group, 44 patients (63%) underwent a surgical procedure, as compared 
to 37 patients (56%) in the reference group. There was an increased odds ratio for 
development of stricture in patients who received preoperative EBRT compared to 
patients who received postoperative EBRT. There was a significantly higher incidence 
of tongue and/or base-of-tongue resections in the stricture group than in the reference 
group. 
 
4.2.4 Radiotherapy as a risk factor 
It was possible to retrieve the complete dose plans and EBRT records for 26 patients in 
the stricture group and for 37 patients in the reference group. Dose-volume histograms 
for the upper 5 cm of the oesophagus are presented in Figure 6. Patients receiving a 
mean dose of over 45 Gy to the superior 5 cm of the oesophagus had a significantly 
higher risk of stricture. 
 
With stratification of the patients according to the two treatment periods, 1987–1999 
and 2000–2005, as shown in Figure 6, the differences in average mean dose and the 
mean percentage DVHs were statistically significant between the cases and the controls 
for 2000–2005 but the differences were not significant for the period 1987–1999. 
 
4.2.5 Multivariate regression analysis of risk factors 
A multivariate logistic regression analysis was conducted for the following parameters: 
mean dose to the oesophagus, NG tube and/or PEG, surgery or no surgery, and primary 
site. This analysis showed that there was a significantly increased risk of stricture in 
patients with NG tube and/or PEG and for patients who received a mean dose of > 45 
Gy to the upper part of the oesophagus. For all other parameters, odds ratios were not 
significant when adjusted for in the multivariate analysis. 
  
4.2.6 Treatment of oesophageal stricture 
The duration between termination of EBRT and diagnosis of stricture ranged from one 
to 132 months, with a mean time of 22 months and a median time of 8 months.  
Oesophagoscopy under general anaesthesia showed grade-II stricture in 41 patients 
(59%). Grade I stricture was found in 19 patients (27%), and grade III stricture in 10 
patients (14%). There was no significant association between the grade of stricture and 
the primary site or tumour stage.  
 
Treatment of the stricture of the upper oesophagus was generally performed by 
endoscopic dilatation under general anaesthesia. In 63 patients, dilatation was 
performed using Savary wire-guided bougies; 53 (84%) could swallow after dilatation 
but in 45 of these patients dilatation had to be repeated. The average number of 
dilatation procedures per patient (according to grade of stricture) was 3.3 for grade I, 
3.0 for grade II, and 4.5 for grade III. Endoscopic dilatation using Savary wire-guided 
dilatations failed to offer any improvement of the swallowing function in 10 patients 
(16%). One patient with grade-II stricture developed a perforation after dilatation with 
Savary-guided bougies.  
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Five patients underwent dilatation using the through-the-scope balloon dilators; two of 
these patients were also dilated with Savary bougies. Four of them could swallow after 
the procedure, but three had to undergo dilatation more than once. 
 
Two patients (grade III) were operated with a resection of the stricture and 
reconstruction with a free vascular flap. One of these patients could swallow after the 
surgical procedure while the other had a postoperative infection and was unable to 
swallow. 
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Table 1. Analysis of risk parameters 
  With stricture
(n=70)
No stricture
(n=66)
OR (univariate) OR (multivariate) 
Stage:  
Stage I 9 (13%) 17 (26%) 0.43 (0.17–1.04)  
Stage II 19 (27%) 10 (15%) 2.09 (0.89–4.90)  
Stage III 20 (29%) 10 (15%) 2.24 (0.96–5.24)  
Stage IV 22 (31%) 22 (33%) 0.92 (0.45–1.88)  
No stage 0 (0%) 7 (11%) .  
Primary site of  tumour:  
Oral  21 (30%) 11 (17%) 2.14 (0.94–4.89) 1.36 (0.33–5.67) 
Oropharyngeal  22 (31%) 13 (20%) 1.87 (0.85–4.11) 1.76 (0.43–7.19) 
Epipharyngeal  5 (7%) 6 (9%) 0.77 (0.22–2.65)  
Hypopharyngeal 5 (7%) 2 (3%) 2.46 (0.46–13.15)  
Laryngeal 14 (20%) 24 (36%) 0.44 (0.20–0.95) 0.58 (0.13–2.54) 
Other sites 3 (4%) 10 (15%) 0.25 (0.07–0.96) 0.22 (0.03–1.49) 
Mucositis:  
Mucositis during EBRT1 49 (70%) 31 (47%) 2.63 (1.30–5.32)  
Enteral feeding:  
Only NG4 tube 31 6  
PEG5 and/or NG4 tube 15 3  
Total incidence of NG4 
tube and/or PEG5 
46 (66%) 9 (14%) 12.14 (5.14–28.66) 11.93 (4.56–31.21) 
Weight:  
Mean weight loss during 
EBRT1 
5.8% (n =41) 3.5% (n =34)  
< 5 % (ref) 16 (23%) 20 (30%)  
> 5 % 25 (36%) 14 (21%) 2.23 (0.88–5.64)  
Missing 29 (41%) 32 (49%) 1.13 (0.50–2.59)  
Surgery:  
No surgery (ref) 26 (37%) 29 (44%)  
Surgery 44 (63%) 37 (56%) 1.33 (0.67–2.63) 1.78 (0.57–5.55) 
Postoperative EBRT 1 
(ref) 
13 (19%) 19 (29%)  
Preoperative EBRT1 31 (44%) 18 (27%) 2.52 (1.01–6.28)  
Hemigloss-tongue2 16 (23%) 3 (5%) 6.22 (1.72–22.50)  
Radiotherapy:  
Mean dose to upper 
oesophagus 
 
< 45 Gy3 (ref) 7 (10%) 25 (38%)  
> 45 Gy3 19 (27%) 12 (18%) 5.65 (1.87–17.10) 7.01 (1.63–30.27) 
Missing 44 (63%) 29 (44%) 5.42 (2.07–14.16) 5.49 (1.60–18.88) 
Abbreviations: 1external beam radiation therapy. 2Hemiglossectomy, tongue resection, base-of-tongue 
resection. 3Gray. 4Nasogastric tube. 5Percutanous endoscopic gastrostomy. 
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Figure 6. DVH for patients with and without stricture, stratified according to year of 
treatment. All patients in the first time period were treated during 1992–1999. 
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4.3 PAPER III – MORBIDITY OF NECK DISSECTION 
A total of 234 patients were included in this study. Patients with major surgery to the 
primary tumor—i.e. laryngectomy or resection followed by reconstruction with a 
vascularised free flap—were excluded (n = 13), as were patients with missing baseline 
data (n = 15). Of the 206 patients remaining, 98 were treated with EBRT as single-
modality treatment, 25 were operated with SOND in combination with EBRT, and 83 
were operated with MRND in combination with EBRT. As expected, the groups 
differed concerning stage and primary site since these parameters are decisive in the 
indication for neck dissection and for the type of neck dissection. The groups also 
differed with regard to gender, with a higher proportion of females treated with SOND. 
Concerning the other clinical parameters collected, the groups were well-matched.  
 
4.3.1 Acute morbidity of ND as single-modality treatment 
To investigate the acute morbidity of neck dissection alone, the neck-dissected patients 
were analysed according to whether they had undergone EBRT preoperatively or 
postoperatively. Of the 108 patients in the neck dissection group, 33 were neck-
dissected before EBRT (postoperative EBRT) and 75 patients were neck-dissected after 
EBRT (preoperative EBRT). No significant differences between the postoperative 
EBRT group and the preoperative EBRT group were found concerning age, gender, 
site, stage, radiotherapy treatment, or chemotherapy treatment. When comparing the 
baseline data for CROM, trismus, and lymphoedema for the postoperative EBRT group 
after surgery to those of the preoperative EBRT group before any treatment was given, 
no significant differences between the two groups were found and due to this finding 
the groups were amalgamated in the ensuing analysis comparing ND patients treated 
with EBRT to patients treated only with EBRT as single-modality treatment.  
Significantly more patients in the postoperative EBRT group (15/33) suffered from 
swallowing disorders than in the preoperative EBRT group (15/75) (p = 0.032).  
 
4.3.2 Morbidity outcomes  
In Figure 7, the difference in CROM and mouth opening between the SOND and 
MRND patients and the patients who were not neck-dissected is shown over time: from 
baseline prior to EBRT to 12 months after treatment. There was a significant reduction 
in all three parameters of CROM and in mouth opening in patients who were operated 
with an MRND two months after treatment (p < 0.001). At 12 months after treatment, 
there was still a significant reduction in cervical rotation but the effect on the other 
parameters had declined to a non-significant level. There was no effect of the SOND on 
the evaluated parameters at any time point during the first year. Furthermore, no 
significant difference in lymphoedema was found between the three groups at 12 
months. 
 
The patient groups compared at 12 months were smaller than at baseline, due to loss of 
patients from recurrences or deaths (n = 53) and for unknown reasons (n = 44).  
 
The total incidence of shoulder disability in neck-dissected patients was 18% (18/102; 
altogether, 6 patients were missing for unknown reasons). Even though a large 
numerical difference, there was no significant difference between patients who were 
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operated with MRND (16/78, 20%) and those who were operated with SOND (2/24, 
8%) (p = 0.23). There was no significant difference in the incidence of swallowing 
disorders between the patients who were not neck-dissected (47/67, 70%), the SOND 
patients (14/20, 70%), and the MRND patients (53/68, 78%) (p = 0.53).  
 
 
 
Figure 7. Comparison of CROM and mouth opening between SOND patients, MRND 
patients, and patients who were not neck-dissected. 
 
 
 
Data regarding CROM at 0, 2, 6, and 12 months were available (all three groups combined) for 206, 
146, 137, and 109 patients. For mouth opening, data were available for 200, 140, 135 and 108 patients 
over time. 
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4.4 PAPER IV – EARLY REHABILITATION  
In total, 456 patients were included in the study, 82 in the pilot study and 374 in the 
prospective study. Of these 374 patients, 205 answered the project-specific 
questionnaire at 6 months after termination of treatment, 84 in the study group and 121 
in the control group. The basic characteristics of the 205 patients were not significantly 
different from those of the 169 patients who did not answer the project-specific 
questionnaire. The groups were well-matched except for a significant difference in the 
number of patients who received chemotherapy (p = 0.004). 
 
4.4.1 Incorporation of the rehabilitation programme 
All patients undergoing EBRT at the southern unit could be included in the clinical 
development programme. There was no difference in time from diagnosis to start of 
treatment between the study group (25.9 days, SD = 30.5) and the control group (25.9 
days, SD = 30.4) (p = 0.99).  
 
4.4.2 Weight loss, survival, and working ability 
There was no significant difference in weight loss between the study group (-5.9 kg) 
and the control group (-6.2 kg) (Table 2). The difference in the incidence of patients 
with weight loss of > 10%, although higher in the control group, was not significant.  
Overall 2-year survival for all patients in the study (n = 374) was 76% (95% CI: 71–
80). There was no significant difference in 2-year survival between the study group (n 
= 190) and the control group (n = 184) (log rank, p = 0.49).  
 
As shown in Table 2, a significantly higher number of patients in the control group who 
had been working before diagnosis had returned to work by 6 months after treatment, 
i.e. more patients in the study group were still on sick leave and had not returned to 
work. 
  
4.4.3 Functional losses 
Patients in the control group reported significantly less swallowing difficulties than 
those in the study group, with a proportional odds ratio (OR) of 2.3 (95% CI: 1.3–4.0). 
In the control group, 58% answered that they could swallow all consistencies of food as 
compared to 35% in the study group (p < 0.001; data not shown in tables). There were a 
significantly higher number of patients using high-kilocalorie/protein supplement in the 
study group (60%) than in the control group (32%) (p < 0.001). Overall incidence of 
swallowing problems was 61% (114/185) and the incidence of patients reporting any 
level of dryness of the mouth was 92% (184/201); incidence of “very great” problems 
with dryness of the mouth was 41% (82/201).  
 
There was a significant difference in the degree of speech problems, with an OR of 2.5 
(95% CI: 1.4–4.4) and an increased risk of being at a worse level in the study group.   
In the total material, the incidence of chewing problems was 61% (113/186); 57% 
(106/186) reported a reduced ability to open the mouth and 70% (133/189) reported 
stiffness of the neck and shoulders 6 months after termination of treatment. There was 
an OR of 1.9 (95% CI: 1.1–3.3) with an increased risk of reduced ability to open the 
mouth in the study group relative to the control group. 
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4.4.4 Quality of life and depression 
Response frequency was lower in EORTC questionnaires than in the project-specific 
questionnaire. No parameters in the EORTC questionnaires or the HADS showed any 
significant difference between the two groups at 6 months after termination of 
treatment. Six months after treatment, the total incidence of depression at any level 
(mild to severe) was 27% (50/183). 
 
Table 2. Comparison of outcome between study group and control group 
   
Characteristics (%) na Study 
group 
Control group p-value Difference (95% CI) 
Weight lossa: 
Stable or increase 
Decrease < 5% 
Decrease 5–10% 
Decrease > 10% 
Mean weight lossb in kg [SD] 
197 
 
 
 
 
 
 
17 (21) 
18 (22) 
27 (33) 
21 (25) 
-5.8 [7.8] 
 
15 (13) 
27 (24) 
30 (26) 
42 (37) 
-6.2 [5.8] 
 
 
 
 
0.23 
0.68 
 
 
 
 
 
-0.4 (-1.5–2.3) 
On sick leave at baseline: 
Situation unchanged at 6 months 
Situation better at 6 months 
 
Not on sick leave at baseline: 
Situation unchanged at 6 months 
Situation worse at 6 months 
22 
 
 
 
133 
 
 
 
7 (64) 
4 (36) 
 
 
29 (55) 
24 (45) 
 
7 (64) 
4 (36) 
 
 
64 (80) 
16 (20) 
 
 
1.0 
 
 
 
0.003 
 
 
 
- 
 
 
25.2 (9.3–41.3) 
Total number of patients 205 84 121   
aNumber of patients included in the analysis. 
 bThe difference in weight loss after controlling for baseline weight was not significant (p = 0.42) and was 
estimated to be 0.7 (-1.0 to 2.4). 
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5 DISCUSSION  
This thesis is based on four studies using three different study populations. All patients 
were part of the ordinary clinical pathway at our institution and they were included in a 
non-selective manner avoiding experimental set-ups. 
   
The aim was to conduct the studies in such a way that the interpretation of findings 
could easily be incorporated into the existing clinical setting. All four studies reached 
this goal, and have influenced patient care at our institution. Unfortunately, this clinical 
approach causes several methodological problems. For instance, patient material is not 
uniform and relationships between key measures and outcomes might be hard to 
establish. However, these problems have to be faced and handled in order to further 
improve treatment, complications, and rehabilitation of head and neck cancer patients.      
 
5.1 PLANNED NECK DISSECTION 
The basic question of the planned neck dissection is to weigh the probability of a 
reduced risk of recurrence in the neck against the probability of morbidity caused by 
surgery. In this work, a third of all patients and a quarter of the patients with a complete 
response in the neck had viable cancer cells in the neck specimen. This is well in line 
with earlier studies and can be interpreted as an indication for planned neck dissection 
for N+-patients after preoperative oncological treatment, regardless of outcome 160-162. 
Other guidelines of today advocate a neck dissection only in patients who do not 
achieve a complete response in the neck, and suggest that patients who are not operated 
on might be controlled with PET-CT 2–3 months after termination of radiotherapy 
81,163. An alternative to PET-CT is diffusion-weighted MRI, which has the advantage of 
not being disturbed by surrounding inflammation and which allows control of tumor 
effect during the course of radiotherapy 164,165. Another alternative is to control the neck 
after radiotherapy with ultrasound with the possibility of fine needle aspiration for 
cytology. This technique has a rather high sensitivity on not irradiated N0 necks but 
studies are lacking on sensitivity in the irradiated neck 166-168. Not to perform a neck 
dissection in patients with a complete response in the neck is the predominant line of 
treatment today 31 and this is also the existing guideline today at our institution for oro- 
and rhinopharyngeal tumours. As shown in this thesis, histopathological outcome and 
disease-specific survival after radiotherapy for patients with tumours of the tonsils or 
base of the tongue were significantly better than in other sites.  
 
The high incidence of viable tumour cells in the neck specimen—as found in many 
studies—might be due to the fact that the neck dissection is often performed six weeks 
after radiotherapy. Many speculate that tumour cell death is not complete at this time, 
and that many of these cells could have undergone cell death at around 12 weeks after 
radiotherapy 169. This would also allow a PET-CT to be performed at 12 weeks, which 
seems to be the best timing to be able to separate inflammation from residual tumour 31. 
The disadvantage would be that the optimal “surgical window” at 4–6 weeks after 
termination of radiotherapy is missed. Quality of radiotherapy might also have an 
influence on differences in anti-tumour activity between studies.  
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We found an overall risk of regional recurrence of around 6%, but the risk was doubled 
if there were viable tumour cells in the neck specimen; these figures are also supported 
in other studies 170. The risk was the same in the group with complete response in the 
neck as for those with palpable residual disease.   
 
In the present study, no comparison between different types of neck dissections was 
done but findings in other studies suggests that less extensive surgery, such as 
supraomohyoidal neck dissection, is as effective as more extensive surgery 171. As 
shown in Paper III, the late morbidity of a supraomohyoidal neck dissection appears to 
be low 90,91,172. We did not do any analysis of acute complications in Paper I and in 
Paper III such as bleeding, wound infection, chyle leak, or delayed healing. The 
incidence of acute morbidity reported in other studies is highly variable, from below 
10% to over 20% 100,160,173-175, and since we lacked a complete morbidity analysis in our 
own material we have had to rely on the findings of other studies.   
 
We found a poor prognosis for patients with viable tumour cells in the neck specimen 
after full-dose radiotherapy. Currently, the most sensitive way to find these cells is a 
neck dissection with histological examination but established methods such as PET-CT 
and ultrasound-guided examination with the possibility for fine-needle aspiration can 
most likely be improved further. Unfortunately, apart from surgery there are no 
additional curative therapies for patients without a complete response to radiotherapy at 
the moment. In our material, a group of 15 patients achieved a complete response in the 
neck but had viable tumour cells in the neck specimen, and this group had a much 
worse outcome than patients with palpable residual disease and viable cells. It does 
seem that these patients were not helped by the neck dissection. A possible reason 
might be that a palpatory residual mass is easier to remove radically than a non- 
palpatory one.  
 
So, should a planned neck dissection be performed in all N-positive patients? The 
question remains unsatisfactorily answered by this study—as well as by earlier studies. 
Obviously further studies are needed, preferably a prospective randomised study—but 
such a study is difficult to perform today due to the changed attitude to neck dissection. 
Instead, at our institution we accomplished a thorough retrospective analysis (after the 
present results had been published) of the outcome in our patients according to primary 
site (unpublished data). From these analyses, it appears that there have to be different 
guidelines for different sites, and even for sub-sites like the mobile part of the tongue 
and the floor of the mouth. As the oncological treatments improve, there is a trend 
towards less surgery, and the trials on radiotherapy and chemotherapy appear to be 
superior in their design to trials on surgical methods. However, surgical methods are 
also developing and some studies using techniques such as robotic surgery show less 
need of additional oncological treatment and also less morbidity 176. At the same time, 
there is a lack of comparisons between adverse events induced by radiotherapy or 
chemotherapy and surgery. These treatment modalities must be evaluated concerning 
outcome and adverse events according to the same standards, in order to provide 
patients with the best possible treatment with the lowest possible morbidity.    
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5.2 OESOPHAGEAL STRICTURE 
As shown in this thesis, the incidence of oesophageal stricture at our institution has not 
changed significantly over the time period 1992-2005 and remains around 3%. Even 
though it is a rare complication, it is associated with considerable morbidity and 
repeated interventions. We identified the use of enteral feeding tubes and a mean dose 
of > 46 Gy to the upper oesophagus as independent risk factors for stricture formation. 
Due to the low incidence of oesophageal stricture, it is difficult to achieve high 
significance for these ratios. Still, the patient material in the present study, 70 cases and 
66 controls, was comparatively large.  
 
In this work, patients treated with chemotherapy were excluded. In studies on patients 
treated with chemoradiotherapy, the incidence of stricture has been reported to be 
around 20% 107,109. There have been few prospective studies, but in the study on 
chemoradiation by Farwell et al. 103, 23% of the patients were found to have 
oesophageal stricture. However, there may have been a selection bias in that study, as 
only 15% of the patients included reported no dysphagia at all. In our material in Paper 
IV, 38% of the patients reported no dysphagia six months after termination of 
treatment, and the speech-language pathologist found no clinical signs of swallowing 
disorders in 26% of the patients. In the study by Francis et al. 109, 60% were found not 
to be suffering from dysphagia. Obviously, patients reporting dysphagia are more likely 
to have an oesophageal stricture.  
 
The relationship between enteral feeding and stricture can be interpreted in different 
ways. It can either be a warning sign for patients who are likely to develop a stricture, 
or the percutanous endoscopic gastrostomy (PEG) or nasogastric-tube (NG-tube) might 
induce stricture formation—directly or indirectly. The possible direct negative effect 
could be oesophageal regurgitation due to the NG tube 177,178. There is evidence that 
PEG placed before the start of treatment prolongs enteral feeding dependency 179 and is 
associated with a reduced quality of life 180. Still, many advocate a prophylactic PEG 
placement before therapy starts to avoid weight loss 181,182 and enteral feeding is 
generally considered to be favourable for patient care 183. Our hypothesis is that 
continued swallowing during and after treatment might prevent stricture formation 184. 
Factors that might prevent patients from swallowing are mucositis, surgery in the oral 
cavity or base of the tongue, and PEG or NG tube; all of these parameters were found 
to be significant risk factors in the univariate analysis. The NG tube itself disturbs 
swallowing, and if patients have a PEG they might be less inclined to swallow. As 
shown by Ryu et al. 185, it is possible to maintain good nutritional status for shorter 
periods using intravenous total parenteral nutrition instead of enteral nutrition. Patients 
who received total parental nutrition had a reduced incidence of aspiration pneumonia 
compared to patients on enteral feeding, although instead there is a risk of catheter-
related infections. The increased risk of pneumonia is most likely related to gastro-
oesophageal reflux, as there does not appear to be an increased risk of aspiration during 
oral intake with an NG tube in place 186.  
 
One interpretation of the results could be that the physician should be more selective 
before equipping patients with tools for enteral nutrition. Instead, some of these patients 
might be better of with total parenteral nutrition—or even just swallowing training and 
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nutritional supplements. Questions can also be raised about the value of nutrition 
support, considering studies such as that of Rabinovitch et al. showing a poorer loco-
regional control in patients receiving nutritional support, even though these patients did 
have less weight loss and a better quality of life 187. 
 
At our institution, dilatation with Savary-guided bougies is still the most common way 
to treat oesophageal strictures. According to the results in this thesis, the procedure is 
safe and successful but often has to be repeated, which is in accordance with the results 
of Piotet et al. 188. The number of patients treated with through-the-scope balloon 
dilatation was low, but in our material it seemed to be just as good as the Savary 
technique. Even though the radial force of a balloon dilatation would appear to be 
better than the combined longitudinal and radial force of the Savary dilator, the 
outcomes of these methods are comparable 189,190.  
 
In our material, no difference in survival was found between the groups in spite of the 
fact that patients in the stricture group went through a number of dilatation 
interventions and suffered from dysphagia. No analysis of quality of life was performed 
in this work, but based on other studies patients with oesophageal stricture can be 
expected to suffer from a reduced quality of life due to dysphagia 191. To reduce the risk 
of stricture formation, radiotherapy at our institution is being continuously developed in 
order to spare organs at risk, such as the upper oesophagus. However, the number of 
patients receiving prophylactic PEG and NG tube is increasing (unpublished data), and 
a thorough discussion on the use of enteral nutrition is needed.   
 
5.3 MORBIDITY OF NECK DISSECTION 
This study complements the study from Paper I in order to evaluate some of the 
morbidity parameters induced by neck dissection combined with radiotherapy, and to 
compare supraomohyoidal neck dissection (SOND) to modified radical neck dissection 
(MRND). As stated in section 5.1, the choice of treatment is always taken by balancing 
the risk of leaving residual tumour after radiotherapy and reducing the risk of 
recurrence with the possible morbidity induced by ND. Most earlier studies on 
morbidity and clinical outcome from neck dissection are retrospective and therefore 
have a low level of evidence while our study is prospective, including longitudinal data, 
making it possible to adjust for baseline values. The chosen morbidity parameters 
studied were cervical range of motion (CROM), trismus, lymphoedema, dysphagia, and 
shoulder disability. According to our findings, the risk of causing a surgical injury by 
SOND is low and the only morbidity found was shoulder disability in 2/24 patients. For 
patients who had gone through a MRND, there was a slight but significant reduction in 
cervical rotation and 16/78 patients suffered from shoulder disability 2 months after 
surgery. An important observation was that morbidity after MRND was significant for 
most of the evaluated parameters two months after treatment, but declined during the 
first post-treatment year. The low rate of objective measurable stiffness in the neck 
contradicts the high rate of self-reported stiffness in the neck and shoulders found in 
Paper IV (70%). The reduced morbidity after a selective ND and the decline over time 
is in line with the findings of Shah et al. 192, even though their study lacked the 
longitudinal approach of the present study. Studies focusing on quality of life also show 
an improvement during the time period from 3 months after treatment to 12 months 
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after treatment 193. There is some evidence of a relationship between reduced quality of 
life and neck dissection 96, but quality of life was not assessed in the present study. 
 
The fact that SOND induced shoulder disability in 2/24 patients (as the only morbidity 
found in this study) does not give a complete picture. For instance, we did not look for 
acute complications to surgery; thus, the incidence is not known for this material. 
However, the incidence of acute post-surgical complications other than shoulder 
disability after a SOND is low according to other studies 79,91. More extensive neck 
dissections, such as the MRND, may be associated with a higher incidence of acute 
post-surgical complications 32. As mentioned in section 5.1, however, there is a need to 
compare oncological treatment to surgery concerning treatment outcomes and 
associated morbidity. A SOND alone does achieve sufficient prevention for regional 
metastasis in N0 oral cavity tumours, but with less morbidity than radiotherapy 194-196. 
Perhaps SOND could replace radiotherapy concerning other diagnoses also—such as 
small oropharyngeal tumours 196,197, but there has to be a proven benefit in morbidity 
outcome.            
 
5.4 EARLY REHABILITATION  
We integrated a programme for early preventive rehabilitation into the clinical pathway 
that is presently in use as a clinical routine. This was achieved without delaying the 
start of treatment, mainly due to our organisation with a coordinating oncology nurse 
making the time schedule for the clinical work-up for every new patient. However, no 
positive outcomes were demonstrated by this programme when comparing patients 
receiving early preventive rehabilitation with patients from the same institution who 
had not been included in the programme. The hard objective outcome measures 
compared were 2-year survival and weight loss. A comparison of functional 
impairment was done by questionnaire; thus, only data concerning the patients’ self-
perceived impairment were collected in this analysis.  
 
There are several possible explanations for the lack of evidence of positive effects of 
the programme. One is simply that the programme itself did not offer any positive 
outcomes. Other rehabilitation programmes using similar exercises to ours but different 
outcome measures have shown positive results 136. Van der Molen et al. were able to 
show improvement concerning dependence of tube-feeding but not in swallowing and 
trismus 198. Carroll et al. compared nine patients who underwent rehabilitation to nine 
patients in a control group, and found improved swallowing in the study group from a 
video-fluoroscopic examination but no improvement in tube-feeding dependency 199. 
Kulbersh et al. used the M.D. Anderson Dysphagia Inventory (MDADI) questionnaire 
to assess patients receiving pre- or post-treatment rehabilitation, and found results in 
favour of the pretreatment group 200; however, objective parameters such as weight loss 
and tube-feeding dependency were lacking. In our work, we found no significant 
difference in tube-feeding dependency but significantly more patients in the 
intervention group used nutritional drinks (data not shown). This finding may reflect 
better-informed patients in the intervention group regarding the importance of nutrition.   
   
Another explanation for the absence of positive results in the rehabilitation programme 
could be low compliance. This was not thoroughly assessed by us, but 37% of the 
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patients in the intervention group answered that they had rarely or never performed the 
exercises provided by the speech-language pathologist (data not shown). Based on this 
figure, low compliance might be a bias that was not adjusted for in this analysis; 
instead, the analysis was done according to intention-to-treat. Perhaps a rehabilitation 
programme like this one should be more intense, with frequent appointments to 
motivate patients better. The patients in our study were meant to start different 
rehabilitation exercises just after their cancer diagnosis and to perform these on a daily 
basis while receiving radiotherapy and in some cases extensive surgery also. It is 
understandable that many of these patients did not follow the rehabilitation programme 
and it remains a challenge to motivate patients with cancer burden during and after 
treatment.  
 
Concerning quality of life, depression, and anxiety, the response frequency was too low 
to be able to interpret these questionnaires. However, no significant difference between 
the intervention and control groups was found. When analysing the total material, there 
was a significant decrease in patients scoring > 7 in anxiety from diagnosis to 6 months 
after treatment: 33% scored > 7 at 6 months as compared to 50% at diagnosis. There 
was the same pattern for depression, but this decrease was not significant: 33% scored 
> 7 at 6 months after treatment as compared to 38% at diagnosis. Similar figures have 
been found in previous studies 201. 
  
The EORTC-QLQ-C30 and EORTC-H&N35 questionnaires were used in this study. 
The patients who answered these seem to have had slightly higher morbidity than 
expected when comparing our results to the results of Hammerlid et al. 202. In our 
material, the mean score for swallowing in EORTC-H&N35 was 25 (95%CI: 20–31); 
the score was exactly the same for pain. For social eating, the mean score was 36 
(95%CI: 29–42). This might partly be explained by the fact that 71% of the patients in 
the present study were at stages III–IV, as compared to 45% in the study by Hammerlid 
et al. The high incidence of stages III–IV in the present study can be explained by the 
fact that radiotherapy was our basic inclusion criterion. 
 
We could not show any positive effects of our intervention with early rehabiliation, 
which might initially seem negative. Instead, we consider this a very important finding. 
Rehabilitation is often presented as a solution to many of the complex problems that 
cancer patients suffer from 129,203. Despite our negative findings, rehabilitation with a 
multidisciplinary approach might be one important part of the care of these patients. 
However, new rehabilitation programmes must be evaluated according to the same 
standards as are new techniques for treatments. There are indications of positive 
outcome regarding well-being from meeting rehabilitation staff, without any 
measurable improvement in functional impairments, but this effect is not enough to 
justify such interventions 157.  
 
Based on the results of the studies described in this thesis, our programme for early 
rehabilitation should be subject to further analysis and modifications.       
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5.5 FUTURE PERSPECTIVES 
There are indications that rehabilitation of selected patient groups is one important way 
to reduce morbidity for head and neck cancer patients. As mentioned above, we will 
further analyse the data from the early rehabilitation project. Firstly, an analysis on 
selected subgroups will be performed. The probable subgroups will be according to 
primary site, sex, age, and pre- or postoperative radiotherapy. More parameters than 
those presented in this thesis will also be assessed. After the analysis of outcomes for 
the subgroups is completed, adjustment of the rehabilitation programme will be done. 
We also intend to present the programme to the patients in a different way, in order to 
improve compliance. These changes will have to be evaluated. Since all patients at our 
institution are now offered rehabilitation, a control group not receiving any 
rehabilitation will be difficult to construct. Instead, changes in the programme for 
specific subgroups will have to be compared to the outcome for the same subgroup 
earlier. Another possibility is to compare outcomes from patients treated at different 
institutions.  
 
Since 2008, the Swedish Head and Neck Cancer Quality Register (SHNC-OR) has 
been operating with a high rate of inclusion. It is possible to connect modules for 
different evaluation parameters to this register. We hope to connect modules for 
specific questionnaires to evaluate the effects of different ways of rehabilitation. These 
might be questionnaires for quality of life (EORTC), depression and anxiety (HADS), 
and swallowing (MDADI). We are investigating the possibility of having data 
automatically transferred from the medical files from the physician, the speech-
language pathologist, and the physiotherapist concerning mouth opening, aspiration, 
and speech. This approach of collecting data will provide us with large populations and 
with the possibility of performing a multi-centre study.  
 
Patients with oesophageal stricture formation will continue to be identified at our 
institution. As there are unpublished data showing increased use of PEG, an increased 
incidence of stricture might be anticipated in accordance with our findings. However, 
as part of the rehabilitation programme patients will be encouraged to continue to 
swallow to the best of their ability even though they receive tube feeding. There are 
also changes in the oncological treatment with chemotherapy and EGFR at our 
institution that might affect the incidence of stricture formation.  
 
As mentioned earlier, we are continuously investigating outcomes for the patients 
treated at our institution and guidelines are adjusted according to these evaluations. The 
need for neck dissection and the levels that have to be included in the neck dissection 
for each primary site is one important issue. Some of these investigations will soon be 
submitted to peer-review journals. The author of this thesis has analysed the outcome 
for patients with tumours in the floor of the mouth, and will continue with cancers of 
the lip.      
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6 CONCLUSIONS 
 
- Our study showed that a clinical evaluation alone was not sufficient to 
determine if a neck dissection was necessary after definitive radiotherapy.  
 
- Viable tumour cells in the neck specimen indicated a poor prognosis, especially 
if there was a clinically complete response in the neck. 
 
- There was an increased risk of development of oesophageal stricture after 
radiotherapy if more than 45 Gy was delivered to a large volume of the upper 5 
cm of the oesophagus. The risk was also increased if the patient used a 
percutanous endoscopic gastrostomy or a nasogastric tube for enteral nutrition 
during or immediately after radiotherapy. 
 
- Treatment of an oesophageal stricture with Savary-Gilliard bougienage or 
through scope balloon dilatation was safe and successful, but it often had to be 
repeated. 
 
- A supraomohyoidal neck dissection had no effect on cervical range of motion, 
trismus, or lymphoedema, while a modified radical neck dissection induced a 
slight reduction in cervical rotation. 
 
- The incidence of shoulder disability after a supraomohyoidal neck dissection 
was approximately 8%, as compared to 20% after a modified radical neck 
dissection.  
 
- We could not show any positive effects of early preventive rehabilitation 
starting before radiotherapy on patient survival, weight loss, functional 
impairment, or quality of life.  
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